An Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of ILV-094 Administered Subcutaneously or Intravenously to Subjects With Psoriasis.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2011
At a glance
- Drugs Fezakinumab; Fezakinumab
- Indications Psoriasis
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2011 Additional location (South Africa) added as reported by ClinicalTrials.gov.
- 07 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Sep 2010 Pfizer added as trial sponsor and affiliate as reported by ClinicalTrials.gov.